A Randomised Multicentre Trial Of Involved Field Radiotherapy Versus Involved Field Radiotherapy Plus Chemotherapy In Combination With Rituximab (Mabthera®) For Stage I – II Low Grade Follicular Lymphoma

For patients with stage I and II low grade follicular lymphoma radiotherapy will cure 40-50% of cases. This study is comparing standard therapy (radiotherapy) and investigational therapy (radiotherapy plus chemotherapy) to see if adding chemotherapy extends the time until the lymphoma progresses in those patient that will not be cured.

Primary Sponsor

Trans Tasman Radiation Oncology Group (TROG)

Collaborating Groups

ALLG (NHLLOW 5); Princess Margaret Hospital, Toronto

Final Accrual

150

Closing Date of Accrual

July 2012

Trial Chairperson

A/Prof Michael Mac Manus, Peter MacCallum Cancer Centre, VIC

Trial Contact

Bev.McClure@petermac.org

Clinical Trial Registration

Related Post

21 October, 2026

Jess’s deeply personal reason for joining TROG’s Km’s for Cancer Research challenge

LATEST NEWS: 21 October 2026 For Jess Synge, taking

14 October, 2026

New FET-PET imaging approach helps target radiotherapy for glioblastoma, FIG trial – TROG 18.06 finds

LATEST NEWS: 14 October 2026 Adding a FET-PET brain